Navigation Links
Biovista Inc. Announces Drug Repositioning Collaboration with Astellas Pharma
Date:12/2/2015

CHARLOTTESVILLE, Virginia, December 2, 2015 /PRNewswire/ --

Biovista announced today that it has entered into a drug repositioning collaboration with Astellas Pharma Inc. The collaboration is focused on identifying new indications for a number of undisclosed Astellas compounds using Biovista's Clinical Outcome Search Space (COSS) technology.

"We look forward to working with the Drug Repurposing and Application Management at Astellas to compliment their work," said Dr. Aris Persidis, President of Biovista. "Our very large scale systematic drug repositioning technology (the "Clinical Outcome Search Space - COSS(tm) offers the advantages of speed, comprehensiveness and depth of clinical outcome exploration, which we hope will help patients in need benefit even more from Astellas drugs," he added.

About Astellas:

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at http://www.astellas.com/en .

About Biovista:

Biovista is a privately held biotechnology company that finds novel uses for existing drugs, and profiles their side effects using their mechanism of action. Biovista is developing its own drug pipeline in multiple indications and is collaborating with the FDA on the prediction of adverse events, as well as with biopharmaceutical companies on indication expansion and de-risking of their portfolios (http://www.biovista.com ).

For further information please contact:

Dr. Aris Persidis, E: arisp@biovista.com


'/>"/>
SOURCE Biovista Inc.
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Biovista and the CFIDS Association of America Achieve Drug Repositioning Milestone with Pre-IND Meeting
2. Neue Publikation von Biovista Inc.: EMR-Daten bestätigen die Vorhersage von Big Data Analytics, dass Hypothyreose einen Risikofaktor für das Neuaufteten von Diabetes Mellitus darstellt
3. New Biovista Inc. Publication: EMR Data Confirm Big Data Analytics Prediction That Hypothyroidism is a Risk Factor for New-onset Diabetes Mellitus
4. Biovista Inc. gibt Zusammenarbeit mit Astellas Pharma zwecks Umpositionierung von Arzneimitteln bekannt
5. Pharmagen Announces First Quarter 2013 Results
6. Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Third Quarter Of 2013 Fiscal Year
7. Vasomedical Announces Financial Results for the First Quarter of 2013
8. TSI Announces 2013 Respiratory Protection Roadshow Training Dates and Locations
9. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
10. Active Life Announces $500K Follow On Series A Investment - Tech Coast Angels Re-up
11. Pentec Health Announces Limited Voluntary Recall of Certain Compounded Prescription Therapies for Renal Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2020)... ... 01, 2020 , ... While coronavirus cases continue to increase across the country, ... organizations remain closed. Because about 80% of blood donations are made at drives hosted ... and blood drive hosts to ensure blood products are readily available for patients. ...
(Date:8/31/2020)... ... August 31, 2020 , ... Continuing on its rapid national ... disinfection and deodorization provider - is proud to announce it has opened doors ... businesses and residents throughout the area. , Germinator provides a 100% safe and ...
(Date:8/27/2020)... ... August 27, 2020 , ... InfoMC, a leading provider of ... their 2020 System and Organizational Controls (SOC) 1® Type 2 and SOC 2® ... assessment. These achievements reflect their long-standing commitment to privacy, security, and risk management, ...
Breaking Medicine Technology:
(Date:9/3/2020)... , ... September 03, 2020 , ... ... memory impairment, has announced the Best Memory Care Facilities in Louisville, KY. The ... features and amenities. , According to the Alzheimer’s Association , 5.6 ...
(Date:9/1/2020)... (PRWEB) , ... September 01, 2020 , ... ... it has completed $3 million convertible note financing, which will be used to ... With the funds from this financing, the company will continue to expand its ...
(Date:8/31/2020)... (PRWEB) , ... August 31, 2020 , ... ... Health Network (AHN), are joining biomedical engineers from Carnegie Mellon University (CMU) to ... for cardiac patients who have undergone open heart surgery. , The AGH/CMU team ...
(Date:8/31/2020)... ... , ... Want to get moving, break up your routine, and make a ... to launch its fourth annual STEPtember campaign in the United States to raise funds ... they are at this moment — encouraging people to move in the ways that ...
(Date:8/31/2020)... ... ... The pandemic and topsy-turvy economic outlook continues to put financial strain on many of us, ... the fat from our monthly expenses and put more into savings, if possible. , “That’s ... a financial safety net in place in case something were to happen to you,” says ...
Breaking Medicine News(10 mins):